Miran Šebeštjen

University of Ljubljana — SI

Medicine · Health Sciences

20h-index1.2kcitations122works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(42), Atherosclerosis and Cardiovascular Diseases(21), Heart Failure Treatment and Management(15), Transplantation: Methods and Outcomes(15), Cardiovascular Function and Risk Factors(14)

Publications122 total

Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction
Journal of Cardiovascular Development and Disease·2025Open Access
SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial
Biomedicines·2025Open Access
Abstract 4365891: PCSK9 inhibitors increase CD34+ but not other endothelial progenitor cells in patients with stable coronary heart disease and increased Lp(a) values
Circulation·2025
Abstract 4365619: Lipoprotein(a) particle characteristics and PCSK9 determine the monocyte subtype distribution in patients with increased Lp(a) levels
Circulation·2025
Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis
Biochemia Medica·2025Open Access
Renal Response to Levosimendan in Advanced Chronic Heart Failure Patients Listed for Heart Transplantation Predicts Early Postoperative Renal Function Course
Journal of Cardiovascular Development and Disease·2025Open Access
Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins
Scientific Reports·2025Open Access
Influence of PCSK9 inhibitors on gene expression of inflammation and hemostasis parameters in patients with coronary artery disease
Atherosclerosis·2025Open Access
Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on vascular wall inflammation parameters
Atherosclerosis·2025Open Access
Elevated Red Cell Distribution Width is Associated with an Increased Allograft Myocardial Scar Burden in Heart Transplant Recipients
The Journal of Heart and Lung Transplantation·2025
Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial
European journal of medical research·2025· 1 citedOpen Access
Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation
Biomedicines·2025· 1 citedOpen Access
Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation
Preprints.org·2024Open Access
Predictors of functional and morphological arterial wall properties in patients with increased lipoprotein (a) before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors
Atherosclerosis·2024Open Access
Gene expression profiling of markers of inflammation, angiogenesis, coagulation and fibrinolysis in patients with coronary artery disease treated with PCSK9 inhibitors
Atherosclerosis·2024Open Access
TNF-alpha predicts endothelial function and number of CD34+ cells after stimulation with G-CSF in patients with advanced heart failure
Atherosclerosis·2024Open Access
Haplotype of the lipoprotein(a) gene variants rs10455872 and rs3798220 is associated with parameters of coagulation, fibrinolysis, and inflammation in patients after myocardial infarction
Atherosclerosis·2024Open Access
Smoking and diabetes attenuate number of CD34+ haematopoietic stem cells in peripheral blood of patients with advanced peripheral artery disease: A cross sectional study
Atherosclerosis·2024Open Access
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values
International Journal of Molecular Sciences·2024· 5 citedOpen Access
Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients
European Journal of Pharmacology·2023· 2 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Irena Keber(16), Andreja Rehberger Likozar(14), Mišo Šabović(11), Bojan Vrtovec(8), Gregor Poglajen(8), R. Okrajšek(7), Sabina Ugovšek(6), Branka Žegura(6), Borut Jug(6), Pavel Poredoš(5), Gregor Zemljič(5), Sabina Frljak(5), Katarina Trebušak Podkrajšek(5), Barbara Eržen(4), Janja Zupan(4), A. Cerar(4), Tina Levstek(4), Janja Pretnar Oblak(3), Nina Vene(3), Barbara Salobir(3)